Established in 2000, BrainsGate is a medical device company committed to developing innovative therapies for patients suffering from Central Nervous System (CNS) diseases.

BrainsGate's platform technology involves electrical stimulation of the Spheno-Palatine Ganglion (SPG), a nervous center known to increase cerebral blood flow.

BrainsGate is exploring several applications for its technology, and is currently focusing on two directions: treatment of acute ischemic stroke, and chronic SPG stimulation to treat vascular dementia patients.

Building on its technology, the Company has developed the ISS, based on a miniature electrode implanted at the roof of the mouth in a minimally invasive, local anesthesia procedure comparable to dental treatment.

In 2008, the Company has completed ImPACT-1, a pilot clinical trial for acute ischemic stroke with promising results. BrainsGate is now running ImPACT-24, a multi-national, randomized, double-blind, sham-controlled pivotal study to assess the safety and efficacy of its treatment for stroke patients in a 24 hour window.

BrainsGate's investors include Johnson & Johnson, Boston Scientific, Elron Electronics Industries, Pitango Venture Capital, Alice Ventures, Agate Medical Investments, and Infinity Ventures. BrainsGate is headquartered in Caesarea, Israel.